Treatment with Tildrakizumab Effective for Scalp Psoriasis in Phase 3b StudyJanuary 14, 2025Psoriatic Arthritis
Cardiac Risks of Newer Psoriasis Biologics vs. TNF Inhibitors ComparedJanuary 7, 2025Psoriatic Arthritis
Combined Clinics, Personalized Medicine for Psoriatic Disease Face BarriersJanuary 2, 2025Psoriatic Arthritis
FDA Approves Ustekinumab Biosimilar Steqeyma, the Seventh of Its KindDecember 19, 2024Psoriatic Arthritis
Adalimumab for Psoriasis: Study Compares Biosimilars Vs. OriginatorDecember 2, 2024Psoriatic Arthritis
Updated Guidance for Psoriatic Arthritis Ultrasound Comes at Time of Growing Use, New TechnologyNovember 18, 2024Psoriatic Arthritis
Therapeutic Drug Monitoring in Rheumatology: A Promising Outlook But Many Barriers to OvercomeOctober 23, 2024Rheumatoid ArthritisSpondyloarthropathiesPediatricsPsoriatic ArthritisLupus & Connective Tissue DiseasesAnkylosing spondylitis
Direct-to-Consumer Testing’s Expansion to Rheumatology Has Benefits but Potential RisksSeptember 27, 2024Business of MedicineRheumatoid ArthritisSpondyloarthropathiesPsoriatic ArthritisLupus & Connective Tissue DiseasesAnkylosing spondylitis
Bimekizumab Gains FDA Approval for Psoriatic Arthritis, Axial SpondyloarthritisSeptember 24, 2024Psoriatic ArthritisSpondyloarthropathies
Rheumatology Clinic Interventions for Smoking, Blood Pressure ‘Make a Big Difference’September 18, 2024Rheumatoid ArthritisSpondyloarthropathiesPsoriatic ArthritisLupus & Connective Tissue DiseasesGoutAnkylosing spondylitis
Topical Tapinarof and Roflumilast for Psoriasis: Where Do they Fit In?September 10, 2024Psoriatic Arthritis
Ustekinumab’s ‘Egregious’ Medicare Part B and D Pricing Differences Led to Federal InterventionAugust 30, 2024Business of MedicinePsoriatic Arthritis
